Phase 1 Study of U3-1287 -Assessment of the safety and pharmacokinetics of U3-1287 in patients with advanced solid tumors

DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 18 人开始时间: 2010年9月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Histologically or cytologically diagnosed advanced solid tumors as listed below which are not curable with, or not eligible for standard treatment(s): Lung, breast, colorectal, prostate, ovarian, cervical, endometrial, gastric, pancreatic, bladder, head and neck, hepatocellular, esophageal, malignant melanoma, or sarcoma
•-ECOG performance status: 0-1

•-History of any of the following diseases within 6 months prior to study enrollment or comorbid medical conditions: heart failure, myocardial infarction, cerebral infarction, active angina, arrhythmia requiring medication, coronary/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thrombosis, deep vein thrombosis, other clinically significant thromboembolic events, or clinically significant pulmonary disease (e.g., COPD or asthma)
•-Patients with any severe or uncontrolled comorbid medical conditions in spite of medications
•-Has brain metastasis with clinical symptoms or requiring treatment
•-Has history of bleeding diathesis (e.g., hemoptysis)
•-Has history of serious drug hypersensitivity such as anaphylactoid reaction

发起方

DAIICHISANKYO Co.,Ltd.